Products for Research Use Only
RegisterLogin

PBT434

CAT: 0804-HY-120475-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-120475-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
PBT434 is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 prevents the loss of substantia nigra pars compacta neurons (SNpc) . PBT434 has the potential for the research of Parkinson’s disease (PD) [1].
CAS Number
1232841-78-9
Product Name Alternative
ATH434
UNSPSC
12352005
Target
α-synuclein
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/pbt434.html
Purity
98.86
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1N(C)C(CNCC)=NC2=C1C(Cl)=CC(Cl)=C2O.Br
Molecular Formula
C12H14BrCl2N3O2
Molecular Weight
383.07
References & Citations
[1]Finkelstein DI, et al. The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease. Acta Neuropathol Commun. 2017 Jun 28;5 (1) :53.|[2]Bailey DK, Clark W, Kosman DJ. The iron chelator, PBT434, modulates transcellular iron trafficking in brain microvascular endothelial cells. PLoS One. 2021 Jul 26;16 (7) :e0254794.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
α-synuclein Aggregation

Alternative Products

CatalogName
T71174-01PBT434 HBr
T72280-01PBT434 methanesulfonate

Popular Products